Eric Floyd, MS, MBA, PhD
Chief Executive Officer
Floyd Strategic Regulatory Consulting
New York, N.Y.
Dr. Eric Floyd is founder and chief executive officer of Floyd Strategic Regulatory Consulting. He has more than 20 years of pharmaceutical and biotechnology experience in regulatory affairs roles of increasing responsibility at Merck, Aventis, Novartis, Lundbeck, Axovant Sciences, and Neurogene, Inc.
Dr. Floyd has a passion for addressing the unmet medical needs of patients with few to no therapeutic options. His specialty is CNS rare/orphan strategic regulatory drug development. Most recently, he served as founder and chief regulatory officer at Neurogene, Inc. Neurogene is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. Dr. Floyd previously served as the global head of regulatory affairs at Axovant Sciences and the US head of regulatory affairs at Lundbeck, where he was responsible for strategic regulatory and clinical development activities related to the company’s approvals of Sabril, Onfi, Northera (orphan approvals) as well as anti-depression and schizophrenia drug approvals.
Dr. Floyd is an adjunct faculty member in the Department of Neuroscience at Harvard Medical School and at Wake Forest University School of Medicine. He serves as a board member to Virpax Pharmaceuticals and Advent Therapeutics Inc., and is also a member of the Board of Trustees of Meharry Medical College.
Dr. Floyd completed his bachelor’s degree in biology from the University of Illinois, a master’s degree in neuroscience from Tennessee State University, a doctorate in neurophysiology from Meharry Medical College, an MBA in pharmaceutical marketing from Saint Josephs’ University, and an International MBA from the INSEAD Business School in Fountainebleu, France. In his spare time, he enjoys mentoring high school and college students and community service projects of Alpha Phi Alpha Fraternity, Inc.